By Julie Steenhuysen CHICAGO (Reuters) - Genome pioneer J. Craig Venter has signed a multi-year deal to sequence and analyze tens of thousands of genomes for Roche's Genentech unit in a deal aimed at identifying new drug targets and biomarkers, the companies said on Wednesday. The deal is one of the biggest yet for Venter's La Jolla, California based Human Longevity Inc (HLI), a start-up formed last March with the goal of sequencing 1 million genomes by 2020. Financial terms were not disclosed. "It's a big deal for HLI and Genentech. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment